Inventive Eye Supplement from Bausch + Lomb Offers
Consumers Greater Ease and Convenience
LAVAL, Quebec, June 16, 2016 /CNW/ -- Valeant
Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today
announced that its wholly owned subsidiary, Bausch + Lomb, a
leading global eye health company, launched new
PreserVision® AREDS 2 Formula + Multivitamin.
PreserVision® is the #1 doctor-recommended eye vitamin
brand specially formulated for people with moderate to advanced
Age-Related Macular Degeneration.
The 2-in-1 formula helps make it simpler for consumers to take
their supplements by reducing the number of pills taken each day
and is the first leading brand to combine the National Eye
Institute recommended AREDS2 nutrient formula with other essential
vitamins and minerals typically found in daily multivitamins.
PreserVision® AREDS 2 Formula + Multivitamin is beta
carotene-free and contains a high level of Vitamin D to support the
needs of older adults.
"We are proud that this new formula directly responds to
consumer feedback and data and can create more convenience for
those we serve," said Joseph C.
Papa, chairman and chief executive officer. "The launch of
PreserVision® AREDS 2 Formula + Multivitamin adds to
Bausch + Lomb's long history of delivering innovation to eye health
and underscores Valeant's commitment to inventive solutions that
address consumers' healthcare needs."
The new PreserVision® AREDS 2 Formula + Multivitamin
is now available in major retailers, including Walgreens, Rite Aid,
Kroger and Amazon.
About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a
multinational specialty pharmaceutical company that develops,
manufactures and markets a broad range of pharmaceutical products
primarily in the areas of dermatology, gastrointestinal disorders,
eye health, neurology and branded generics. More information about
Valeant can be found at www.valeant.com.
Forward-looking Statements
This press release contains forward-looking statements.
Forward-looking statements may generally be identified by the use
of the words "anticipates," "expects," "intends," "plans,"
"should," "could," "would," "may," "will," "believes," "estimates,"
"potential," "target," or "continue" and variations or similar
expressions. These statements are based upon the current
expectations and beliefs and are subject to certain risks and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. Readers are
cautioned not to place undue reliance on any of these
forward-looking statements. These forward-looking statements
speak only as of the date hereof. Valeant undertakes no obligation
to update any of these forward-looking statements to reflect events
or circumstances after the date of this press release or to reflect
actual outcomes, unless required by law.
PreserVision is a registered trademark of Bausch & Lomb
Incorporated or its affiliates. AREDS and AREDS2 are registered
trademarks of The U.S. Department of Health and Human Services
(HHS).
Contact Information:
Laurie W. Little
laurie.little@valeant.com
or
Elif McDonald
elif.mcdonald@valeant.com
514-856-3855
877-281-6642 (toll free)
Media:
Renée Soto
or
Chris Kittredge/Jared Levy
Sard Verbinnen & Co.
212-687-8080
Logo -
http://photos.prnewswire.com/prnh/20101025/LA87217LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/valeant-pharmaceuticals-announces-launch-of-new-preservision-areds-2-formula--multivitamin-300285751.html
SOURCE Valeant Pharmaceuticals International, Inc.